GlassScriptPhysician profile
Amit M Patel
NPI 1043577646
$17,965.32
in general payments reported to CMS, 2019-2025
26 companies · $6,496 in 2025
The $6,496 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $561 · 2021: $652 · 2022: $1,898 · 2023: $3,687 · 2024: $4,144 · 2025: $6,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,875 · Education: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,026.51 |
| Consulting Fee | $1,875.00 |
| Education | $424.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,092.58 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Sobi, INC | $1,787.13 | 2023-2025 | |
| Lilly USA, LLC | $1,600.09 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $1,488.75 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Astrazeneca Pharmaceuticals LP | $1,366.08 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,285.82 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,225.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $984.70 | 2021-2025 | |
| Radius Health, INC. | $779.38 | 2022-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $522.26 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $473.44 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $452.83 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $383.60 | 2024-2025 | Acthar |
| Pfizer INC. | $367.67 | 2022-2025 | |
| Genzyme Corporation | $225.16 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.07 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $187.44 | 2024-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $165.93 | 2022-2025 | Lupkynis |
| Sandoz INC. | $89.74 | 2025 | Hyrimoz, Jubbonti |
| Kiniksa Pharmaceuticals International, Plc | $89.07 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $85.02 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $40.99 | 2023 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2025 | Dupixent |
| Abbott Laboratories | $23.32 | 2022 | |
| Mylan Institutional INC. | $19.29 | 2023 | Hulio |
| Boston Scientific Corporation | $13.11 | 2023 | Interlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.